Three separate research teams have failed to replicate a 2016 primate study showing that treatment with a primate version of monoclonal antibody Entyvio (vedolizumab, Takeda Pharmaceutical Co. Ltd.), led to prolonged suppression of viremia in SHIV-infected monkeys.